Rafael Pharmaceuticals Enters into Research Collaboration with Roswell Park Comprehensive Cancer Center to Evaluate the Effects of CPI-613® (Devimistat) on Esophageal Cancer
Stock Information for Rafael Holdings Inc. Class B
Loading
Please wait while we load your information from QuoteMedia.